Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019448 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Stage IV Melanoma
Recurrent Melanoma

Interventions

DRUG: gp100 antigen
DRUG: interleukin-2

Sponsor

National Cancer Institute (NCI)